Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dollar General Corp. (DG) vs Twist Bioscience Corp (TWST) Price & Performance

Dollar General Corp.Trade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Dollar General Corp. vs Twist Bioscience Corp — how do they compare? Dollar General Corp. trades at $121.25 (market cap $26.50B), while Twist Bioscience Corp trades at $92.63 (market cap $5.77B). The key difference: Dollar General Corp. is far larger — about 4.6× Twist Bioscience Corp's market cap, and Dollar General Corp. pays a 1.96% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

DGTWST
Market Cap
$26.50B$5.77B
Sector
Consumer StaplesHealth
52-Week High
$156.26$102.88
52-Week Low
$95.94$24.16
Enterprise Value
$40.95B$5.69B
Dividend Yield
1.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dollar General Corp.

Dollar General (DG) trades at $123.44, up 3.8% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.00 exceeding expectations of $1.89. Revenue growth continues at $40.61B for 2025, while profit margins face pressure at 3.63%. Recent news highlights the company's back-to-school initiatives and margin expansion efforts.

The outlook remains positive with a $128.45 consensus price target representing 4% upside. Key opportunities include continued same-store sales growth and margin recovery, while risks involve consumer spending sensitivity and competitive pressures in discount retail. The technical setup suggests near-term resistance around $125-$128 levels.

Twist Bioscience Corp

TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.

The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST